Publications by authors named "Joseph T Beck"

Claim this Profile
A
A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer.
Michael R Shafique, Terrence L Fisher, Elizabeth E Evans, John E Leonard, Desa Rae E Pastore, Joseph T Beck

Clin Cancer Res· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.
Patrick Yung Wen, Jordi A Rodon, Warren Mason, Joseph T Beck, John DeGroot

ESMO Open· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study.
Carlo Gambacorti-Passerini, Sergey Orlov, Li Zhang, Fadi Braiteh, Huiqiang Huang, Joseph T Beck

Am J Hematol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial.
Joyce O'Shaughnessy, Katarina Petrakova, Gabe S Sonke, Pierfranco Conte, Carlos L Arteaga, Joseph T Beck

Breast Cancer Res Treat· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.
Elisabeth Quoix, Hervé Lena, Gyorgy Losonczy, Frédéric Forget, Christos Chouaid, Joseph T Beck

Lancet Oncol· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events.
Swaminathan P Iyer, Joseph Taddeus Beck, A Keith Stewart, Jatin Shah, Kevin R Kelly

Br J Haematol· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
Joseph Thaddeus Beck, Amen Ismail, Christina Tolomeo

Cancer Treat Rev· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy.
Cristina Saura, Johanna Bendell, Guy Jerusalem, Shaun Su, Qinhua Ru, Joseph T Beck

Clin Cancer Res· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis